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There is a substantial need for biomarkers to distinguish latent stage from active
Mycobacterium tuberculosis infections, for predicting disease progression. To induce
the reactivation of tuberculosis, we present a new experimental animal model modified
based on the previous model established by our group. In the newmodel, the reactivation
of tuberculosis is induced without administration of immunosuppressive agents, which
might disturb immune responses. To identify the immunological status of the persistent
and chronic stages, we analyzed immunological genes in lung tissues from mice infected
withM. tuberculosis. Gene expression was screened using cDNAmicroarray analysis and
confirmed by quantitative RT-PCR. Based on the cDNA microarray results, 11 candidate
cytokines genes, which were obviously up-regulated during the chronic stage compared
with those during the persistent stage, were selected and clustered into three groups: (1)
chemokine genes, except those of monocyte chemoattractant proteins (MCPs; CXCL9,
CXCL10, CXCL11, CCL5, CCL19); (2) MCP genes (CCL2, CCL7, CCL8, CCL12); and
(3) TNF and IFN-γ genes. Results from the cDNA microarray and quantitative RT-PCR
analyses revealed that the mRNA expression of the selected cytokine genes was
significantly higher in lung tissues of the chronic stage than of the persistent stage. Three
chemokines (CCL5, CCL19, and CXCL9) and three MCPs (CCL7, CCL2, and CCL12)
were noticeably increased in the chronic stage compared with the persistent stage by
cDNA microarray (p < 0.01, except CCL12) or RT-PCR (p < 0.01). Therefore, these six
significantly increased cytokines in lung tissue from the mouse tuberculosis model might
be candidates for biomarkers to distinguish the two disease stages. This information can
be combined with already reported potential biomarkers to construct a network of more
efficient tuberculosis markers.
Keywords: active tuberculosis, persistent tuberculosis, mouse model, chemokines, lung tissues, cDNA
microarrays
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INTRODUCITON
Approximately 5–10% of latent infections of tuberculosis (TB)
become active over the lifetimes of infected individuals (Sia
and Wieland, 2011). Therefore, the most effective strategy for
TB control is the early diagnosis of an active infection in
individuals with latent TB followed by preventive chemotherapy
(Verhagen et al., 2013; Abouda et al., 2015; Lee et al., 2015b).
Currently, in vitro studies of blood lymphocyte stimulation with
Mycobacterium tuberculosis (Mtb)-specific antigens or detection
of cytokines in plasma are the most popular assays used for the
diagnosis of active infections. The interferon-gamma (IFN-γ)
release assay (IGRA) is a highly sensitive and specific method
for detecting Mtb infection (Greveson et al., 2013), but it cannot
distinguish latent from active infections efficiently (Lange et al.,
2012; Targowski et al., 2014; Cho et al., 2016), despite it has been
commonly used for the screening and clinical diagnosis of these
two stages, respectively.
One method to find more suitable biomarkers of TB is to
compare the cytokines in sera from patients with active or latent
stages of infection with those from healthy individuals (Weiner
and Kaufmann, 2014; Jayakumar et al., 2015; Walter et al., 2016).
However, consistent results have not been obtained because the
number of cytokines analyzed is often too small, and the types
of assays used to detect them vary between studies. Thus, a more
systematic approach for analyzing all cytokines is needed, and the
results obtained can be combined with reported TB biomarkers
to construct a network of potential markers. This study therefore
aimed to identify cytokines that could be superior or additively
informative to IFN-γ for the rapid diagnosis of TB and for
distinguishing between latent and active infections.
Instead of human samples, we analyzed lung tissues from
mice infected with Mtb strain Erdman, which was established
by our group based on the modified Cornell mouse model for
tuberculosis. Because of their heterogeneous genetic background,
human samples such as peripheral blood lymphocytes or plasma
often show diverse immune responses, and, moreover, may
reflect an indirect phenomenon far from the pathological
lesions. Therefore, we suggest that an animal study will deliver
consistent information of in situ immune responses because
infected lung tissues from the same genetic background are
evaluated. Through cDNA microarray and quantitative RT-PCR
analyses, we obtained information on immune response-related
genes expressed differentially according to the persistent and
chronic stages, and attempted to identify biomarker candidates
to distinguish the two infection stages of TB.
MATERIALS AND METHODS
Bacterial Strains
The infecting strain, Mtb Erdman, was grown in Middlebrook
7H9 broth (Difco, Oxford, UK) supplemented with 0.05% Tween
80 and albumin-dextrose-catalase enrichment.
Mice Infection Model
C57BL/6 mice were infected through the aerosol route with Mtb
(200–300 CFUs/lung), using a Glas-Col aerosol exposure system.
For the chronic stage group, the mice were not treated with anti-
TB agents after bacilli infection. For the persistent stage group,
the mice were treated with anti-TB agents beginning at 4 weeks
post-infection to induce the persistent stage of infection. As the
first therapy, the infected mice were treated with INH and PZA
for 5 weeks and subsequently with INH and EMB for a further
3 weeks. The drugs were delivered ad libitum by adding the
following concentrations to drinking water: 100µg/mL of INH,
600µg/mL of EMB, and 600 µg/mL of PZA. All drug-containing
water was replaced weekly. Water consumption was monitored
to determine the delivered daily dose (INH: 26.5 ± 0.9 mg/kg;
PZA and EMB: 132.6 ± 4.7 mg/kg). To maintain the persistent
stage of infection, mice that had completed the drug therapy were
supplied with regular drinking water for 1–2weeks. A third group
of mice not subjected to bacilli infection or drug therapy was used
as the healthy controls.
For the reactivation stage, the mice in the persistent stage were
supplied with regular drinking water for further 4 weeks. Chronic
stage mice were sacrificed at 16 weeks post-infection without any
drug therapy. At the indicated time points, 3–4 mice in each
group were sacrificed, the lungs and spleens were removed and
homogenized in phosphate-buffered saline, and dilutions of the
tissue homogenates were plated on 7H10 agar to enumerate the
CFUs.
Histopathology
One lone of the lungs was fixed in 4% phosphate-buffered
formaldehyde and embedded in paraffin. Sections of ∼5 µm
thickness were prepared and stained with haematoxylin and
eosin. Acid-fast Mtb bacilli in the lung tissue were detected
by Ziehl-Neelsen staining. The stained slides were observed
under a light microscope (×40). Lung inflammation lesions were
evaluated by ImageJ software (National Institutes of Health,
Bethesda, Maryland, USA). Results were represented as the
percentage of area with lesions.
RNA Isolation
Total RNA was isolated from lung tissues of all three groups
of mice, using the RNeasy Mini Kit (Qiagen, Valencia, CA,
USA). The quality and quantity of total RNA were assessed
by measuring the absorbance ratios of total RNA at 260/280
and 260/230 nm with the NanoDrop-2000 spectrophotometer
(Thermo Fisher Scientific, Wilmington, DE, USA), as well as the
28S/18S ratio and RNA integrity number with the Agilent 2100
BioAnalyzer.
cDNA Synthesis and Microarray Analysis
For cDNA synthesis, reverse transcription was performed with
M-MLV Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA).
Each 40 µL reaction included 8 µL of 5 × first-strand buffer,
8 µL of dNTP (2.5mM), 1 µL of oligo (dT) primer (0.5 µg/µL),
2 µL of Moloney murine leukemia virus reverse transcriptase,
4 µL of dithiothreitol (0.1M), 3 µg of RNA template, and
a suitable volume of RNase-free water for each sample. This
mixture was incubated at 42◦C for 2 h. For microarray analysis, a
GeneChip R© (Mouse Gene 2.0 ST Array X 21; Affymetrix, Santa
Clara, CA, USA) containing more than 698,000 total probes and
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26,515 RefSeq (Entrez) genes was used in this study. Samples
were prepared and handled according to the manufacturer’s
recommendations. Significant transcripts with expression value
changes of 2-fold or greater were selected, using a t-test with p<
0.05.
Real-Time Reverse Transcription (RT)-PCR
All primers for the DNA oligonucleotides and the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were synthesized by the IDT real-time PCR primer design
program. Real-time PCR was performed with FastStart Universal
Power SYBR Green Master (ROX) (Roche Diagnostics,
Indianapolis, IN, USA) using the 7500 Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA). In brief, 1 µL of
cDNA was added to a PCR mixture consisting of 12.5 µL of
FastStart SYBR green master mix, 11 µL of RNase-free water,
and 10 µM of each primer (Table S4). The real-time PCR
running protocol was 10 min at 95◦C, followed by 40 cycles of
95◦C for 15 s and 60◦C for 1 min. The dissociation curve was
obtained by heating from 60 to 95◦C. For data analysis, StepOne
version 2.0.2 software (Applied Biosystems) was used to calculate
the levels of target gene expression in samples relative to the
expression level in the control samples, using the comparative
cycle threshold method (11CT). Expression values for target
genes were normalized against that of GAPDH.
Statistical Analysis
Results are presented as the mean and standard error of the
mean (SEM). For the quantitative RT-PCR analysis, Student’s
unpaired t-test (two-tailed) was used. For analysis of CFU
score and inflammation score, one-way ANOVA was used. Data
were analyzed using the GraphPad Prism version 5.01 program
(GraphPad Software Inc., USA). A p < 0.05 was considered
statistically significant.
RESULTS
Colony-Forming Unit Counts and
Histopathological Findings in Lung Tissues
from Mice Infected with Mtb Bacilli
The mouse model for Mtb infection established in our laboratory
is very similar to infection in humans in terms of infection
route and relapse after treatment, which were confirmed by
colony-forming unit (CFU) counts (Figure 1A). To induce a
chronic/active infection in mice that is comparable to an active
infection in humans, one group of mice were not treated
with any anti-TB agents for 16 weeks after aerosol infection
with 200–300 CFU of Mtb. To mimic post-chemotherapeutic
persistent infection, another group of mice were administered
isoniazid (INH) and pyrazinamide (PZA; from the 4th to 9th
weeks) followed by INH and ethambutol (EMB; from the 9th
to 12th weeks) after aerosol infection. This persistent stage was
confirmed by inducing reactivation of bacilli growth without
further administration of anti-TB agents (from the 12th to 20th
weeks). Upon reactivation, the CFU increased by more than 104
in the lungs (Figure 1B) and 103 in the spleens (Figure 1C) at
the 20th week, which mimicked the reactivation of Mtb infection
and suggested that the persistent stage in the mice model might
be similar to post-chemotherapeutic stage in humans.
For the chronic stage in untreated mice, the CFU reached to
more than 105 in the lungs (Figure 1B, p < 0.001 compared to
healthy group) and more than 104 in the spleens (Figure 1C, p
< 0.001 compared to healthy group) at 16 weeks after aerosol
infection. During induction of the persistent stage, the CFU
declined to<103 in both lungs (Figure 1B) and 102 in the spleens
(Figure 1C) at 8 weeks after initiating INH+PZA treatment.
Then, during the stable persistent stage, which established after
starting of 8 or 9 weeks of the anti-TB drug treatment, the
CFU reached to ∼102 in both the lungs (Figure 1B, p < 0.001
compared to chronic stage) and the spleens (Figure 1C, p <
0.001 compared to chronic stage) on persistent stage-1 (1 day)
or persistent stage-2 (1 week) after completion of drug treatment.
Histopathology of chronic stage lung tissues revealed multiple
dispersed granulomas, infiltrated mostly with macrophages and
neutrophils (Figure 2B) compared with those of healthy group
(Figure 2A). At persistent stage-1 (1 day after completion of
drug treatment), some pathology of chronic infection was still
observed (data not shown), suggesting the tissues had not
recovered from the inflammation. The granuloma formation
and inflammation were reduced at persistent stage-3, which was
2 weeks after the completion of drug treatment (Figure 2C),
suggesting a stable persistent stage had been reached. This
persistent stage was supported by multiple granuloma formation
of reactivation stage (Figure 2D), which was observed 6 weeks
after no anti-TB drug treatment following completion of
the INH+PZA or INH+EMB treatment. The percentage of
inflammation lesions of each stage showed the similar pattern
compared to CFU results. The score for lung inflammation
lesions were 8.0–12.2% in healthy group, 34.1–36.5% in chronic
group, 24.8–27.1% in persistent group and 42.2–47.9% in
reactivation group, respectively (Figure 2E). The difference
between healthy and reactivation groups is significant (p< 0.01).
Screening of Differentially Expressed
Genes in Lung Tissues by Microarray
Analysis
In an attempt to screen gene expression in lung tissues, a
GeneChip R© containing more than 698,000 total probes and
26,515 RefSeq (Entrez) genes was used. Compared with that in
the healthy group, 577 genes in chronic stage mice and 114 genes
in persistent stage mice were found to be up-regulated by more
than 2-fold (Figure 3A). Among them, the expression levels of
205 genes were increased in both the persistent and chronic
stages. On the other hand, 39 genes in chronic stage mice and
7 genes in persistent stage mice were down-regulated compared
with those in the healthy group (Figure 3A). Eleven genes were
down-regulated in both the persistent and chronic stages.
Importantly, compared with those in the persistent stage, the
expression levels of 410 genes were increased by more than 2-
fold, and that of 31 genes bymore than 5-fold, in the chronic stage
(Figure 3B). The immune response genes that were increased
by more than 2-fold are listed. Based on the microarray results,
we identified 18 immune response-related genes which were
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FIGURE 1 | CFU in lungs or spleens after aerosol infection with M. tuberculosis bacilli.(A) Experimental design for TB infection. For the chronic stage, mice were not
treated with any anti-TB agents for 16 weeks after aerosol infection of 200–300 colony-forming units (CFU). For the persistent infection, isoniazid (INH) and
pyrazinamide (PZA; from the 4th to 9th weeks) and INH and ethambutol (EMB; from the 9th to 12th weeks) were administrated after aerosol infection. For the
reactivation, the persistent stage mice were no longer treated with anti-TB agents (from the 12th to 20th weeks). (B,C) The lungs and spleens from each stage were
homogenized in PBS, and dilutions were plated on 7H10 agar to enumerate CFUs. N = 2–8 in each group. One-way ANOVA was used for statistical analysis. ***p <
0.001.
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FIGURE 2 | Histopathological findings. (A–D) One lung was fixed in
phosphate-buffered formaldehyde and embedded in paraffin. Sections were
stained with haematoxylin and eosin. Acid-fast Mycobacterium tuberculosis
bacilli in the lung tissue were detected by Ziehl-Neelsen staining. The stained
slides were observed under a light microscope (×40 magnification) and the
representative picture are shown. (E) Lung inflammation lesions were
evaluated by ImageJ software (National Institutes of Health, Bethesda,
Maryland, USA). Results were represented as the percentage of area with
lesions. N = 2–8 in each group. Each dot denotes each individual. One-way
ANOVA was used for statistical analysis. **p < 0.01.
obviously up-regulated during the chronic stage compared with
those during the persistent stage (Figure 3C, shown in red in the
heat map). Among these 18 genes, we selected 11 cytokine genes
for further study. The other seven genes were excluded because
they are cytokine receptor genes [viz., interleukin (IL)-12β1
receptor, IL-12β2 receptor, IL-2 receptor, IL-7 receptor, IL-21
receptor, IL-27 receptor, and C-X-C motif chemokine receptor
6 (CXCR6)]. In addition to these immune response genes, the
other notably increased genes in the chronic stage were inducible
nitric oxide synthase 2, matrix metallopeptidase 12, CD86, CD80,
and molecules responsible for T cell activation such as CD3,
CD6, lymphocyte-specific protein tyrosine kinase, interleukin-
2-inducible T-cell kinase, and linker for activation of T cells
(Table 1). The cDNAmicroarray data are available at NCBI GEO
(accession No.: GSE97835).
Analysis of 11 Cytokine Genes by cDNA
Microarray Assay and Quantitative RT-PCR
Based on their immunological functions, the 11 selected genes
were clustered into three groups: (1) chemokines, excluding
monocyte chemoattractant proteins (MCPs; CXCL9, CXCL10,
CXCL11, CCL5, and CCL19); (2) MCPs (CCL2, CCL7, CCL8,
and CCL12); and (3) tumor necrosis factor (TNF) and IFN-γ.
The expression levels of all 11 genes were significantly higher
in the chronic stage group than in the persistent stage or
healthy groups. Although the expression of chemokines such as
CXCL9, CXCL10, CXCL11, CCL5, and CCL19 was higher in the
persistent stage group than in the healthy group in the cDNA
microarray analysis (Figure 4A; Table S2) and quantitative RT-
PCR (Figure 5A; Table S2), the difference between the chronic
stage vs. the persistent stage or healthy group was more obvious
and significant (Tables S1, S3). Among the 11 genes, CXCL9
expression in the chronic stage was notably high, with a 7.2-fold
increase over that of the persistent stage (p = 0.0067) as shown
by quantitative RT-PCR (Table S1). More interestingly, our
microarray study showed that the expression of MCPs was higher
during the chronic stage than in the persistent stage (Figure 4B;
Table S1). The quantitative RT-PCR analysis (Figure 5B; Table
S1) showed similar results, with expression increases of 4.24-
fold for CCL2 (p = 0.0069), 5.16-fold for CCL7 (p = 0.0029),
3.78-fold for CCL8 (p = 0.0094), and 5.25-fold for CCL12 (p =
0.0081). Among them, CCL8 expression was significantly higher
in the persistent stage mice than in the healthy group (7.21-
fold, p = 0.0179), whereas the CCL2 (0.99-fold, p = 0.4698),
CCL7 (1.789-fold, p = 0.1474), and CCL12 (1.11-fold, p =
0.8058) expression levels did not differ significantly between
these two mouse groups. Therefore, we suggest the MCPs to
be further candidate biomarkers to distinguish each infection
stage efficiently. Although, mRNA of TNF-α and IFN-γ (two
well-known cytokine indicators for TB) were increased in lung
tissues in the microarray analysis (Figure 4C; Table S1), we could
not obtain significant results by quantitative RT-PCR (Figure 5C;
Table S1).
DISCUSSION
Although, biomarkers to detect Mtb infection or to distinguish
disease stages have been studied for several decades,
improvements have not beenmade successfully. Ideal biomarkers
for TB should be key biological factors expressed differentially
among the infection stages and specific to the disease. IFN-
γ, the indicator used in the IGRA, has been considered a
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FIGURE 3 | Differentially expressed genes in the various infection stages of tuberculosis. For microarray analysis, a GeneChip® (Affymetrix) containing more than
698,000 total probes and 26,515 RefSeq (Entrez) genes was used. Genes with significantly changed expression values (p < 0.05) were selected. (A) A Venn diagram
of the differentially expressed genes in the lung tissues. Up-regulation >2-fold, and down-regulation <1/2-fold. (B) Number of genes with increased expression in the
chronic stage vs. the persistent stage. (C) Heat map showing the 18 genes chosen for further study.
potential biomarker for identifying the presence or absence of
Mtb infection and its infection stages (Greveson et al., 2013;
Targowski et al., 2014; Weiner and Kaufmann, 2014). Although
IGRA, which is more specific and sensitive than the tuberculin
skin test, is currently the most commonly used assay to diagnose
latent TB infection (Cho et al., 2016), it cannot distinguish
latent infection from active TB (Metcalfe et al., 2011). Therefore,
to more accurately distinguish between these two stages, the
selective combination of immune response genes has been under
study. Among them, the protein levels of CXCL10 (IP-10; Tonby
et al., 2015; Wergeland et al., 2015; Xiong et al., 2016; regulated
under IFN-γ) and levels of mRNA Kim et al., 2015 or protein
(Jeong et al., 2015; Lee et al., 2015a) for CXCL9, CXCL10, and
CXCL11 have been pointed out by other researchers. These
studies were mostly performed with blood mononuclear cells
after stimulation with Mtb-specific antigens. Only several papers
tested plasma levels without antigen stimulation. One study
suggested the possibility of using IFN-γ, IL-4, CCL4, CCL7, and
CXCL10 from unstimulated plasma samples to discriminate
active TB from latently infected contacts and to monitor anti-TB
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TABLE 1 | Expression of immune response-related genes in the chronic and
persistent stages of tuberculosis infection by cDNA microarray analysis.
Chronic/
persistent
Gene
symbol
Gene description
5.8 Nos2 nitric oxide synthase 2, inducible
5.2 LOC630751 interferon-inducible GTPase 1-like
5.2 Ly6i lymphocyte antigen 6 complex, locus I
4.2 Slamf8 signaling lymphocytic activation molecule family
member 8
3.6 Tnf tumor necrosis factor
3.6 Mmp12 matrix metallopeptidase 12
3.5 Cxcl10 chemokine (C-X-C motif) ligand 10
3.4 Cxcr6 chemokine (C-X-C motif) receptor 6
3.2 Ccr5 chemokine (C-C motif) receptor 5
3.1 Ccl8 chemokine (C-C motif) ligand 8
3.0 Xcr1 chemokine (C motif) receptor 1
2.8 Ifng interferon gamma
2.8 Ccl19 chemokine (C-C motif) ligand 19
2.8 Slamf7 signaling lymphocytic activation molecule family
member 7
2.7 Tnfrsf9 tumor necrosis factor receptor superfamily,
member 9
2.7 Cd72 CD72 antigen
2.7 Fcgr1 Fc receptor, IgG, high affinity I
2.7 Ccl7 chemokine (C-C motif) ligand 7
2.6 Cxcl9 chemokine (C-X-C motif) ligand 9
2.6 Cd86 CD86 antigen
2.5 Cd3e CD3 antigen, epsilon polypeptide
2.5 Mmp13 matrix metallopeptidase 13
2.5 Cd4 CD4 antigen
2.5 Ccl2 chemokine (C-C motif) ligand 2
2.4 Msr1 macrophage scavenger receptor 1
2.4 Cd3g CD3 antigen, gamma polypeptide
2.4 Cd80 CD80 antigen
2.4 Gm2023 predicted gene 2023/ chemokine (C-C motif) ligand
19
2.4 Cd6 CD6 antigen
2.4 Cxcl11 chemokine (C-X-C motif) ligand 11
2.3 Ctss cathepsin S
2.3 Ccl19 chemokine (C-C motif) ligand 19
2.3 Cd68 CD68 antigen
2.3 Cxcl5 chemokine (C-X-C motif) ligand 5
2.3 Lck lymphocyte protein tyrosine kinase
2.2 Ly9 lymphocyte antigen 9
2.2 Slamf6 signaling lymphocytic activation molecule family
member 6
2.2 Socs1 suppressor of cytokine signaling 1
2.2 Itk IL2 inducible T cell kinase
2.2 Ccl19 chemokine (C-C motif) ligand 19
2.2 Ccl19 chemokine (C-C motif) ligand 19
2.2 Cd5 CD5 antigen
2.2 Cd40lg CD40 ligand
2.1 Ccl20 chemokine (C-C motif) ligand 20
2.1 Cd52 CD52 antigen
(Continued)
TABLE 1 | Continued
Chronic/
persistent
Gene
symbol
Gene description
2.1 Cd8b1 CD8 antigen, beta chain 1
2.1 Il23r interleukin 23 receptor
2.1 Slamf9 signaling lymphocytic activation molecule family
member 9
2.1 Ccl12 chemokine (C-C motif) ligand 12
2.0 Cxcr3 chemokine (C-X-C motif) receptor 3
2.0 Il21r interleukin 21 receptor
2.0 Lat linker for activation of T cells
For microarray analysis, a GeneChip® (Affymetrix) containing more than 698,000 total
probes and 26,515 RefSeq (Entrez) genes was used. Among them, genes relevant to
immune responses and increased more than 2-fold are shown.
treatment (Mihret et al., 2013). Another study suggested CXCR3
ligands (CXCL9 and CXCL10) as useful surrogate markers in
plasma for diagnosing active TB clinically (Lee et al., 2015a).
More recently, when plasma levels of IL-2, IL-4, IL-6, IL-10,
TNF-α, and IFN-γ were determined during the follow-up of
anti-TB chemotherapy, slow responders showed significantly
higher IL-2 and IL-4 levels at baseline than did fast responders,
effectively differentiating the two responder types (Iqbal et al.,
2016). Considering these reports, a systematic analysis of
immune response genes is essential to understand diverse
immune reactions in tuberculosis.
In this study, we adopted a mouse model for Mtb infection,
which had been established in our laboratory based on the
Cornell model infection with the Mtb (Ha et al., 2003). The
expression of cytokines and other immune response-related
genes was evaluated in lung tissues from mice in the post-
chemotherapeutic persistent stage and in the chronic stage
(comparable to active infection in humans), as well as in healthy
mice. To evaluate the in situ immune responses, RNA was
purified directly from the lung tissues without any further antigen
stimulation in vitro, and cDNA microarray and quantitative
RT-PCR analyses were performed.
First, our data showed that both mRNA levels of IFN-γ and
CXCL10 were increased during the chronic stage compared with
the persistent stage. IFN-γ and CXCL10 (Holm et al., 2014;
Latorre et al., 2014; Jeong et al., 2015; Tonby et al., 2015;
Wergeland et al., 2015) are already well-knownmajor biomarkers
for TB. Our results are in agreement with those of previous
studies, and are not surprising given that CXCL10 is known
to be under the regulation of IFN-γ. However, our study also
showed that the mRNA expression of CXCL10 was much higher
than that of IFN-γ; therefore, CXCL10 may be easier to detect.
Furthermore, because the changes in CXCL10 levels were more
significant than those in IFN-γ levels (Figures 4A,C, 5A,C),
CXCL10 could be amore useful biomarker to screen the infection
stages of TB.
In addition to IFN-γ and CXCL10, our study suggested that
mRNA levels of chemokines such as CXCL9, CXCL11, CCL5, and
CCL19 were increased distinctly in the chronic stage relative to
the persistent stage (Figures 4A, 5A). Similar to our results, the
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FIGURE 4 | cDNA microarray analysis of 11 genes expressed differentially in
the various infection stages of tuberculosis. For microarray analysis, a
GeneChip® (Affymetrix) containing more than 698,000 total probes and
26,515 RefSeq (Entrez) genes was used. Genes with expression level changes
of 2-fold or greater were selected. (A) Chemokines, excluding myocyte
chemoattractant proteins (MCPs). (B) MCPs. (C) Tumor necrosis factor (TNF)
and interferon (IFN)-γ. *p < 0.05, **p < 0.01, ***p < 0.001.
plasma levels of CXCL9, CXCL10, and CXCL11 were reported in
another study to be higher in active TB patients than in healthy
persons (Lee et al., 2015a), whereas the IFN-γ levels did not differ
in that paper. A recent study also showed that protein levels of
CXCR3 ligands, such as CXCL9 and CXCL11, were higher in
sera from TB patients than in sera from healthy persons (Lee
et al., 2015a). However, there has been no report about CCL5 and
CCL19 until this present work.
In our study, although the net mRNA expression levels of
CCL5 and CCL19 were lower than that of CXCL9 or CXCL11,
FIGURE 5 | Quantitative RT-PCR analysis of 11 genes expressed differentially
in the various infection stages of tuberculosis. Real-time PCR was performed
with FastStart Universal Power SYBR Green Master (ROX) (Roche Diagnostics)
using the 7,500 Real-Time PCR system (Applied Biosystems). In brief, 1 µL of
cDNA was added to a PCR mixture consisting of 12.5 µL of FastStart SYBR
green master mix, 11 µL of RNase-free water, and 10 µM of each primer. The
PCR protocol was 10 min at 95◦C, and 40 cycles of 95◦C for 15 s and 60◦C
for 1 min. StepOne version 2.0.2 software (Applied Biosystems) was used to
calculate the expression levels of target genes in the samples, relative to that in
the control samples, using the comparative cycle threshold method (11CT).
Expression values for target genes were normalized against that of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (A) Chemokines,
excluding myocyte chemoattractant proteins (MCPs). (B) MCPs. (C) Tumor
necrosis factor (TNF) and interferon (IFN)-γ. *p < 0.05, **p < 0.01, ***p <
0.001.
the significant differences between the chronic stage and the
persistent or healthy stages suggest these ligands as biomarker
candidates. One recent paper assessing blood mononuclear cells
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from tuberculosis patients suggests that the polymorphism (TT
genotype) of CCL5 may play an important role to decrease CCL5
expression in T cells to interfere immunity against tuberculosis
(Singh et al., 2017). Interestingly, among selected chemokines,
CXCL9 distinguished the persistent stage from healthy group
notably (41.85-fold).
Besides IFN-γ, CXCL10, and CXCL9, which have been
intensively studied by other researchers, our study revealed that
mRNA levels of MCPs such as CCL2, CCL7, CCL8, and CCL12
were increased in lung tissues. MCPs induce the recruitment
of multiple subsets of leukocytes, including monocytes. A few
studies have reported CCL2 (Mihret et al., 2013) and CCL7
(Mihret et al., 2013) to be increased in sera of patients with
active TB, which is highly comparable to our results in the lungs
(Figures 4B, 5B). Recently, genetic polymorphism of CCL2 has
been suggested to be associated with the susceptibility to TB
(Nonghanphithak et al., 2016). Another study has suggested the
association of CCL2 with the pathogenesis of TB, by showing
that the 6 kDa early secretory antigenic target (ESAT-6) of
Mtb-induced CCL2 production in mouse bone marrow-derived
macrophages and that the inhibition of p38 enhanced ESAT-
6-induced CCL2 production (Ma et al., 2016). Therefore, the
increase of CCL2 and CCL7 in our mouse Mtb infection model
is also applicable for the understanding of the pathogenesis of
human TB. Another important piece of information in our study
is the increased expression of CCL12 in lung tissues of the chronic
stage (Figures 4B, 5B). The involvement of CCL12 in TB has not
been reported before.
Taking the results together, through screening of ∼30,000
genes using in situ infected lung tissues, we have identified several
TB biomarkers which might be suitable for distinguishing the
chronic/active stage from the post-chemotherapeutic persistent
stage. Our study showed that the levels of MCPs in lung tissues
could distinguish between the two stages significantly. We are
the first to observe significant up-regulation of CCL5, CCL19,
and CCL12 in the chronic stage of TB. Furthermore, the MCPs
including CCL2, CCL7, CCL8, and CCL12, which were evaluated
in a few studies, might be useful biomarkers to distinguish the
infection stages of this disease. Quantitative RT-PCR showed
the expression levels of all four MCPs to be significantly higher
in the chronic stage than in the persistent stage, whereas only
CCL8 distinguished the persistent stage (7.21-fold) from the
healthy group. CCL2, CCL7, and CCL12 could not distinguish
the persistent stage mice from the healthy group.
Research on TB diagnosis is progressing to the point of
finding markers in sputum samples (Marais and Pai, 2007;
Sia and Wieland, 2011). The advantage of the sputum-based
test is that whereas routine clinical samples are obtained from
relatively inaccessible sites (Lee, 2015), sputum can be easily
monitored (Jacobs et al., 2016). Moreover, the trend is to
omit the process of antigen stimulation, because diagnosis
using Mtb antigen-induced cytokines/chemokines by blood
mononuclear cells is considered inconvenient, labor intensive,
and time consuming (Yang et al., 2014). Therefore, we are
certain that our study covering multiple gene arrays will provide
abundant information regarding the comparison of tissues
and sera.
In conclusion, we have identified several new biomarkers
that may be applied for TB screening and for the diagnosis of
chronic/active TB or post-chemotherapeutic persistent stage. Of
particular importance, we suggest evidence that the combined
use of multiple indicators may raise the sensitivity and specificity
of TB detection.
ETHICS STATEMENT
All animal experiments were performed in compliance with
the Yonsei University Institutional Animal Care guidelines,
and protocols were reviewed and approved by the Institutional
Animal Care and Use Committees of the Laboratory Animal
Research Center at Yonsei University Health System (Permit
Number: 2014-0301).
AUTHOR CONTRIBUTIONS
SC and IC designed research. SP, SB, and YJ performed
experiments and analyzed the data. IC wrote the manuscript. All
authors reviewed the final version of the manuscript.
ACKNOWLEDGMENT
This research was supported by a grant of the Korea Health
Technology R&D Project through the Korea Health Industry
Development Institute (KHIDI), funded by the Ministry of
Health and Welfare, Republic of Korea (Grant number:
HI13C0847).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fcimb.
2017.00314/full#supplementary-material
REFERENCES
Abouda, M., Yangui, F., Triki, M., Kammoun, H., Khouani, H., and Charfi,
M. R. (2015). [Tuberculosis prevention]. Rev. Pneumol. Clin. 71, 159–167.
doi: 10.1016/j.pneumo.2014.06.002
Cho, H., Kim, Y. W., Suh, C. H., Jung, J. Y., Um, Y. J., Jung, J. H., et al.
(2016). Concordance between the tuberculin skin test and interferon gamma
release assay (IGRA) for diagnosing latent tuberculosis infection in patients
with systemic lupus erythematosus and patient characteristics associated with
an indeterminate IGRA. Lupus 25, 1341–1348. doi: 10.1177/09612033166
39381
Greveson, K., Goodhand, J., Capocci, S., Woodward, S., Murray, C., Cropley, I.,
et al. (2013). Yield and cost effectiveness of mycobacterial infection detection
using a simple IGRA-based protocol in UK subjects with inflammatory bowel
disease suitable for anti-TNFalpha therapy. J. Crohns. Colitis 7, 412–418.
doi: 10.1016/j.crohns.2012.08.010
Ha, S. J., Jeon, B. Y., Kim, S. C., Kim, D. J., Song, M. K., Sung, Y. C., et al.
(2003). Therapeutic effect of DNA vaccines combined with chemotherapy in
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 9 July 2017 | Volume 7 | Article 314
Park et al. Chemokines in Tuberculous Mice Lungs
a latent infection model after aerosol infection of mice with Mycobacterium
tuberculosis. Gene Ther. 10, 1592–1599. doi: 10.1038/sj.gt.3302057
Holm, L. L., Rose, M. V., Kimaro, G., Bygbjerg, I. C., Mfinanga, S. G., Ravn, P.,
et al. (2014). A comparison of interferon-gamma and IP-10 for the diagnosis of
tuberculosis. Pediatrics 134, e1568–e1575. doi: 10.1542/peds.2014-1570
Iqbal, N. T., Hussain, R., Shahid, F., and Dawood, G. (2016). Association of plasma
cytokines with radiological recovery in pulmonary tuberculosis patients. Int. J.
Mycobacteriol. 5, 111–119. doi: 10.1016/j.ijmyco.2015.12.003
Jacobs, R., Tshehla, E., Malherbe, S., Kriel, M., Loxton, A. G., Stanley, K., et al.
(2016). Host biomarkers detected in saliva show promise as markers for the
diagnosis of pulmonary tuberculosis disease and monitoring of the response
to tuberculosis treatment. Cytokine 81, 50–56. doi: 10.1016/j.cyto.2016.
02.004
Jayakumar, A., Vittinghoff, E., Segal, M. R., MacKenzie, W. R., Johnson, J. L.,
Gitta, P., et al. (2015). Serum biomarkers of treatment response within a
randomized clinical trial for pulmonary tuberculosis. Tuberculosis 95, 415–420.
doi: 10.1016/j.tube.2015.04.011
Jeong, Y. H., Hur, Y. G., Lee, H., Kim, S., Cho, J. E., Chang, J., et al. (2015).
Discrimination between active and latent tuberculosis based on ratio of
antigen-specific to mitogen-induced IP-10 production. J. Clin. Microbiol. 53,
504–510. doi: 10.1128/JCM.02758-14
Kim, S., Lee, H., Kim, H., Kim, Y., Cho, J. E., Jin, H., et al. (2015).
Diagnostic performance of a cytokine and IFN-gamma-induced chemokine
mRNA assay after Mycobacterium tuberculosis-specific antigen stimulation
in whole blood from infected individuals. J. Mol. Diagn. 17, 90–99.
doi: 10.1016/j.jmoldx.2014.08.005
Lange, B., Vavra, M., Kern, W. V., and Wagner, D. (2012). Development of
tuberculosis in immunocompromised patients with a positive tuberculosis-
specific IGRA. Int. J. Tuberc. Lung Dis. 16, 492–495. doi: 10.5588/ijtld.11.
0416
Latorre, I., Díaz, J., Mialdea, I., Serra-Vidal, M., Altet, N., Prat, C., et al. (2014).
IP-10 is an accurate biomarker for the diagnosis of tuberculosis in children. J.
Infect. 69, 590–599. doi: 10.1016/j.jinf.2014.06.013
Lee, J. Y. (2015). Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc.
Respir. Dis. 78, 47–55. doi: 10.4046/trd.2015.78.2.47
Lee, K., Chung, K., Jung, K., Kim, K., Park, K., and Sheen. K. (2015a). CXCR3
ligands as clinical markers for pulmonary tuberculosis. Int. J. Tuberc. Lung Dis.
19, 191–199. doi: 10.5588/ijtld.14.0525
Lee, J. Y., Jung, Y.W., Jeong, I., Joh, J. S., Sim, S. Y., Choi, B., et al. (2015b). Immune
parameters differentiating active from latent tuberculosis infection in humans.
Tuberculosis 95, 758–763. doi: 10.1016/j.tube.2015.08.003
Ma, J., Jung, B. G., Yi, N., and Samten, B. (2016). Early secreted antigenic target of
6 kDa of Mycobacterium tuberculosis stimulates macrophage chemoattractant
protein-1 production by macrophages and its regulation by p38 mitogen-
activated protein kinases and interleukin-4. Scand. J. Immunol. 84, 39–48.
doi: 10.1111/sji.12447
Marais, B. J., and Pai, M. (2007). New approaches and emerging technologies
in the diagnosis of childhood tuberculosis. Paediatr. Respir. Rev. 8, 124–133.
doi: 10.1016/j.prrv.2007.04.002
Metcalfe, J. Z., Everett, C. K., Steingart, K. R., Cattamanchi, A., Huang, L.,
Hopewell, P. C., et al. (2011). Interferon-gamma release assays for active
pulmonary tuberculosis diagnosis in adults in low- and middle-income
countries: systematic review and meta-analysis. J. Infect. Dis. 204(Suppl. 4),
S1120–S1129. doi: 10.1093/infdis/jir410
Mihret, A., Bekele, Y., Bobosha, K., Kidd, M., Aseffa, A., Howe, R., et al.
(2013). Plasma cytokines and chemokines differentiate between active
disease and non-active tuberculosis infection. J. Infect. 66, 357–365.
doi: 10.1016/j.jinf.2012.11.005
Nonghanphithak, D., Reechaipichitkul, W., Namwat, W., Lulitanond, V.,
Naranbhai, V., and Faksri, K. (2016). Genetic polymorphisms of CCL2
associated with susceptibility to latent tuberculous infection in Thailand. Int.
J. Tuberc. Lung Dis. 20, 1242–1248. doi: 10.5588/ijtld.16.0017
Sia, I. G., and Wieland, M. L. (2011). Current concepts in the management of
tuberculosis.Mayo Clin. Proc. 86, 348–361. doi: 10.4065/mcp.2010.0820
Singh, B., Anbalagan, S., and Selvaraj. P. (2017). Regulatory role of CCL5
(rs2280789) and CXCL10 (rs56061981) gene polymorphisms on intracellular
CCL5 and CXCL10 expression in pulmonary tuberculosis. Hum. Immunol. 78,
430–434. doi: 10.1016/j.humimm.2017.03.008
Targowski, T., Chelstowska, S., and Plusa, T. (2014). IGRA as a predictive factor
of silent pulmonary changes in individuals following exposure to tuberculosis.
Lung 192, 869–874. doi: 10.1007/s00408-014-9637-y
Tonby, K., Ruhwald, M., Kvale, D., and Dyrhol-Riise, A.M. (2015). IP-10measured
by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium
Tuberculosis infection. Sci. Rep. 5:9223. doi: 10.1038/srep09223
Verhagen, L. M., Zomer, A., Maes, M., Villalba, J. A., Del Nogal, B., Eleveld, M.,
et al. (2013). A predictive signature gene set for discriminating active from
latent tuberculosis in Warao Amerindian children. BMC Genomics 14:74.
doi: 10.1186/1471-2164-14-74
Walter, N. D., Miller, M. A., Vasquez, J., Weiner, M., Chapman, A., Engle, M., et al.
(2016). Blood transcriptional biomarkers for active tuberculosis among patients
in the United States: a case-control study with systematic cross-classifier
evaluation. J. Clin. Microbiol. 54, 274–282. doi: 10.1128/JCM.01990-15
Weiner, J. III., and Kaufmann, S. H. (2014). Recent advances towards
tuberculosis control: vaccines and biomarkers. J. Intern. Med. 275, 467–480.
doi: 10.1111/joim.12212
Wergeland, I., Pullar, N., Assmus, J., Ueland, T., Tonby, K., Feruglio, S.,
et al. (2015). IP-10 differentiates between active and latent tuberculosis
irrespective of HIV status and declines during therapy. J. Infect. 70, 381–391.
doi: 10.1016/j.jinf.2014.12.019
Xiong, W., Dong, H., Wang, J., Zou, X., Wen, Q., Luo, W., et al. (2016).
Analysis of plasma cytokine and chemokine profiles in patients with and
without tuberculosis by liquid array-based multiplexed immunoassays. PLoS
ONE 11:e0148885. doi: 10.1371/journal.pone.0148885
Yang, Q. T., Cai, Y., Zhao, W., Wu, F., Zhang, M., Luo, K., et al. (2014). IP-10 and
MIG are compartmentalized at the site of disease during pleural and meningeal
tuberculosis and are decreased after antituberculosis treatment. Clin. Vaccine
Immunol. 21, 1635–1644. doi: 10.1128/CVI.00499-14
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Park, Baek, Cho, Jang, Kim and Choi. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 10 July 2017 | Volume 7 | Article 314
